Thermo Fisher Scientific (TMO): Strong Q3 Guidance and Broadening Demand Support Multi-Year Outlook

ClearBridge Investments, a global equity manager, recently published third-quarter 2026 commentary for its "Large Cap Growth Strategy". The letter can be downloaded here. In the third quarter, leadership among large growth stocks shifted from high-momentum semiconductor names to companies with clearer AI monetization paths. The ClearBridge Large Cap Growth Strategy outperformed its Russell 1000 Growth Index benchmark, benefiting from strong stock selection and disciplined valuation approaches. Despite volatility and a selloff in higher-beta AI stocks, the S&P 500 Index and NASDAQ Composite posted gains. The benchmark Russell 1000 Growth Index posted a modest gain of 0.9% while the Russell 1000 Value Index was up 2.6%. The Strategy broadened exposure across select semiconductor, AI infrastructure, and diversifying growth companies, while maintaining measured momentum exposure. The rebalance of the Russell 1000 Growth Index increased semiconductor weights and lowered software exposure, aligning with a thoughtful expansion into the AI and semiconductor infrastructure ecosystem. Overall, the strategy's focus on quality and valuation proved advantageous amidst market shifts. Also, check the fund's top five holdings to see its best picks in 2026.

In its third quarter 2026 investor letter, ClearBridge Large Cap Growth Strategy highlighted Thermo Fisher Scientific Inc. (NYSE:TMO) as a notable contributor. Thermo Fisher Scientific Inc. (NYSE:TMO) is a life science company that focuses on providing life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services. On October 05, 2026, Thermo Fisher Scientific Inc. (NYSE:TMO) closed at $676.76 per share. Over the past month, Thermo Fisher Scientific Inc. (NYSE:TMO) returned 10.48%, and its shares are up 23.56% over the past year. Thermo Fisher Scientific Inc. (NYSE:TMO) has a market capitalization of $250.23 billion, and its stock has traded within a 52-week range of $435.27 to $694.33.

ClearBridge Large Cap Growth Strategy stated the following regarding Thermo Fisher Scientific Inc. (NYSE:TMO) in its Q3 2026 investor letter

"Outside of AI, Thermo Fisher Scientific Inc. (NYSE:TMO) was a positive contributor. Thermo Fisher Scientific continued to benefit from its second-quarter earnings beat, with resilient biopharma consumables and pharmaceutical product development end markets and healthy third-quarter guidance supporting the prospect of an accelerating business into 2027. The breadth of recovery across those end markets is particularly important after a more difficult period for life sciences spending."

Thermo Fisher Scientific Inc. (NYSE:TMO) ranks 34 on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. As per our database, 118 hedge fund portfolios held Thermo Fisher Scientific Inc. (NYSE:TMO) at the end of the second quarter, which was 115 in the previous quarter. While we acknowledge the potential of Thermo Fisher Scientific Inc. (NYSE:TMO) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In another article, we discussed Thermo Fisher Scientific Inc. (NYSE:TMO) and shared a list of best healthcare stocks to buy according to hedge funds. In addition, please check out our hedge fund investor letters Q3 2026 page for more investor letters from hedge funds and other leading investors.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

This article is originally published at Insider Monkey.